1 Title: Protection afforded by post-infection SARS-CoV-2 vaccine doses: a cohort

- 2 study in Shanghai
- 3
- 4 Bo Zheng^{1†}, Bronner Gonçalves^{2†}, Pengfei Deng^{3†}, Weibing Wang^{1,4}, Jie Tian¹,
- 5 Xueyao Liang¹, Ye Yao⁵*, Caoyi Xue³*
- 6
- 7
- 8 1 Department of Epidemiology, School of Public Health, Fudan University, Shanghai
 9 200032, China
- 10 2 Department of Comparative Biomedical Sciences, School of Veterinary Medicine,
- 11 University of Surrey, Guildford, UK
- 12 3 Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai,
- 13 200120, China
- 14 4 Key Laboratory of Public Health Safety of Ministry of Education, Fudan University,
- 15 Shanghai 200032, China
- 16 5 School of Public Health, Shanghai Institute of Infectious Disease and Biosecurity,
- 17 Fudan University, Shanghai 200032, China
- 18
- 19
- 20 **†** These authors contributed equally to this work.
- 21 * Corresponding authors:
- 22 Dr. Ye Yao
- 23 School of Public Health, Fudan University, 138 Yi Xue Yuan Road, Shanghai 200032,
- 24 China (e-mail: <u>yyao@fudan.edu.cn</u>).
- 25 Dr. Caoyi Xue
- 26 Shanghai Pudong New Area Center for Disease Control and Prevention, 3039
- 27 Zhangyang Road, Shanghai, 200120, China (e-mail: xuecaoyi83@163.com)
- 28
- 29
- 30
- 31
- 32
- 33

34 ABSTRACT

35 *Background:* In many settings, a large fraction of the population has both been 36 vaccinated against and infected by SARS-CoV-2. Hence, quantifying the protection 37 provided by post-infection vaccination has become critical for policy. We aimed to 38 estimate the protective effect against SARS-CoV-2 reinfection of an additional 39 vaccine dose after an initial Omicron variant infection.

40 *Methods*: We report a retrospective, population-based cohort study performed in 41 Shanghai, China, using electronic databases with information on SARS-CoV-2 42 infections and vaccination history. We compared reinfection incidence by post-43 infection vaccination status in individuals initially infected during the April-May 2022 44 Omicron variant surge in Shanghai and who had been vaccinated before that period. 45 Cox models were fit to estimate adjusted hazard ratios (aHR).

46 Results: 275,896 individuals were diagnosed with RT-PCR-confirmed SARS-CoV-2 47 infection in April-May 2022; 199,312/275,896 were included in analyses on the effect 48 of a post-infection vaccine dose. Post-infection vaccination provided protection 49 against reinfection (aHR 0.82; 95% CI 0.79-0.85). For patients who had received one, 50 two or three vaccine doses before their first infection, hazard ratios for the post-51 infection vaccination effect were 0.84 (0.76-0.93), 0.87 (0.83-0.90) and 0.96 (0.74-52 1.23), respectively. Post-infection vaccination within 30 and 90 days before the 53 second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44-54 0.58), and 0.67 (0.61-0.74), respectively. Moreover, for all vaccine types, but to 55 different extents, a post-infection dose given to individuals who were fully vaccinated 56 before first infection was protective.

Conclusions: In previously vaccinated and infected individuals, an additional vaccine
 dose provided protection against Omicron variant reinfection. These observations will
 inform future policy decisions on COVID-19 vaccination in China and other countries.

Keywords: COVID-19, vaccine effectiveness, hybrid immunity, reinfection, Omicron
variant.

- 63
- 64
- 65
- 66

67 1 Introduction

68 Four years after the first reports of severe acute respiratory syndrome 69 coronavirus 2 (SARS \Box CoV \Box 2) infection, the Coronavirus disease (COVID-19) 70 pandemic continues to be a global concern, especially due to the risk of emergence of 71 new variants [1, 2]. In most countries, the variant that is currently epidemiologically 72 dominant is the Omicron[3, 4], which, due to its increased transmissibility and high 73 number of mutations, led to significant increases in the number of infections in 74 2022[5]. Omicron variant infections were first observed in China in December 75 2021[3], and in Shanghai, the spread of the Omicron BA.2 sublineage led to a 76 substantial increase in COVID-19 incidence between February 26 and June 30, 77 2022[6].

78 In December 2022[7], an important change in the COVID-19 policy in China, 79 namely the end of most social distancing measures and of mass screening activities, 80 was associated with a second surge in SARS-CoV-2 infections in Shanghai. The 81 current circulation of the virus in the Shanghainese population and reports of vaccine 82 fatigue mean that it is important to estimate the protective effect of vaccination 83 against reinfection in this population. In this study, we aimed to quantify the effect of 84 vaccine doses given after a first infection on the risk of subsequent infection. For that, 85 we used data collected during the first Omicron variant wave, when hundreds of 86 thousands of individuals tested real-time polymerase chain reaction (RT-PCR)-87 positive for SARS-CoV-2 infection[8] in Shanghai, of which 275,896 individuals in 88 Pudong District. The fact that the population in Shanghai was mostly SARS-CoV-2 89 infection naïve before the spread of the Omicron variant provides a unique 90 opportunity to estimate the real-world benefit of post-infection vaccine doses in a 91 population that was first exposed to infection during a relatively short and well-92 defined time window. We further investigated whether the number of pre-infection 93 vaccination doses modified the protective effect of the post-infection dose against 94 Omicron BA.5 sublineage. To avoid ambiguity in the text, in the following sections, 95 we often refer to vaccine doses given after the initial infection as "post-infection 96 vaccination" or "post-infection vaccine dose".

97 2 Results

98 2.1 Demographic characteristics of the study population

99

Of the 275,896 individuals with RT-PCR-confirmed SARS-CoV-2 infection

during the first Omicron variant wave (from April 1 to May 31, 2022) in Pudong,
Shanghai, 1,227 individuals died from reasons unrelated to COVID-19 between the
first infection and November 2022 and were excluded from our analysis. Most first
infections (243,906, 88.8%) occurred in April; for 306 (0.1%) individuals,
information on the date of first infection was not available. In April 2022, more than
half of the study population (68.6%) had completed full vaccination and one third
(34.4%) had received booster vaccination.

To assess the effect of post-infection vaccination, the analytic sample consisted of 199,312 individuals (**Figure 1**). 85,804 were women (43.1%); 836 (0.4%) had sex information missing. 38.1% of the study participants were aged 20 to 39 years and only 0.9% were aged 0 to 6 years (see **Table 1** and **Table S1** for additional information).

112 2.2 Vaccination after first Omicron variant infection

113 Figure 2 (Panel A) shows vaccination coverage in the analytic population over 114 time. In April 2022, a series of emergency epidemic prevention measures, including 115 mass screening with Nucleic Acid Amplification Tests (NAATs), city-wide lockdown, 116 home quarantine of residents, were implemented in Shanghai, leading to the 117 temporary suspension of vaccination in April and May 2022. By the end of the study 118 period, January 2023, 69.5% (190,815/274,363) of the study participants had 119 completed full vaccination, and 38.4% booster vaccination (Figure S1). Vaccination 120 coverages for the first, second, third, and fourth vaccine doses were 72.7%, 67.6%, 121 37.4% and 0.3%, respectively.

122 As mentioned above, only participants who had received vaccination before the 123 first infection were included in this analysis. After infection, 10,241 (5.1%), 5,096 124 (2.6%), and 810 (0.4%) individuals received another vaccine dose in August, and 125 during the periods from September to November 2022 and from December 2022 to 126 January 2023, respectively. Between their first infection, in April-May 2022, and 127 January 2023, 17.4% (2,466/14,131) of the study participants who had one pre-128 infection dose received a second dose of COVID-19 vaccine, and 13.8% 129 (12,886/93,087) of those who had received two pre-infection doses received a third 130 vaccine dose. Only 1.0% (142/14,131) of the study participants who had one pre-131 infection dose received two post-infection vaccine doses, and 0.2% (144/93,087) of 132 those who had received two pre-infection doses received two post-infection doses

(Table S2). All individuals with three pre-infection vaccine doses who received a
fourth dose (795/92,094, 0.9%) received the post-infection dose in December 2022;
for 793 of these participants, the post-infection vaccination received in December was
their second booster vaccination (for the other 2, their fourth dose was the first
booster vaccination; see *Supplementary Appendix* for more information about vaccine
policy in Shanghai).

139 2.3 SARS-CoV-2 reinfections

Among the study participants, 48,651/199,312 (24.4%) had SARS-CoV-2 reinfection. The median age of individuals with no evidence of reinfection was 41.7 years (IQR: 31.0, 55.7 years), and of individuals with confirmed SARS-CoV-2 reinfection, 45.8 years (IQR: 34.0, 55.9 years) (**Table S1**). The median time interval between the first infection and reinfection was 244.7 days (IQR: 237.4, 250.0), which implies that the risk of misclassifying a long infection as a reinfection was low.

146 Figure 2 (Panels B and C) shows the cumulative incidence of SARS-CoV-2 147 reinfection by vaccination status. Overall, individuals who were not vaccinated after 148 their first infection were more often reinfected compared to those who received post-149 infection vaccination. The percentage of female individuals who became reinfected 150 was lower than that of male individuals (22.4% vs. 26.1%; **Table 1**); and reinfection 151 was more common in participants aged 40 to 59 years compared to those aged 20 to 152 39 (29.4% vs. 22.4%). Individuals originally from other provinces had a slightly 153 higher risk of reinfection compared to individuals from Shanghai (20.9% vs. 18.9%). 154 The risks for retired individuals, for those of working age who were not working, and 155 for those working were 22.5, 21.0, and 20.8%, respectively.

156 2.4 Vaccine effectiveness

157 For individuals who had received at least one pre-infection vaccine dose, post-158 infection vaccination was protective against reinfection (adjusted hazard ratio [aHR] 159 0.82, 95% CI 0.79, 0.85). As shown in **Figure 3**, this protective effect was observed 160 in subgroups defined by the number of pre-infection vaccine doses: aHR of 0.84 (95%) 161 CI, 0.76, 0.93) and 0.87 (95% CI, 0.83, 0.90) for one and two pre-infection doses 162 respectively; and for patients with three vaccine doses prior to infection, the 163 association was not statistically significant (aHR: 0.96 [0.74, 1.23]). When analyses 164 are stratified by partial and full vaccination status before the first infection, post-165 infection vaccination was protective (aHR 0.76 [0.68, 0.84], and 0.93 [0.89, 0.97],

166 respectively); and among individuals who had received booster vaccination before the 167 first Omicron variant wave in Shanghai, the hazard ratio estimate was consistent with 168 a more limited effect (aHR: 0.95 [0.75, 1.22]). Note that the overlapping categories 169 between classification of pre-infection vaccination status and the number of pre-170 infection vaccinations (Table S3). For comparison, results for individuals who had 171 not been vaccinated before their first infection are shown in the Supplementary 172 Appendix (supplementary section "Effect of post-infection vaccination in individuals 173 with no history of vaccination before infection" and Table S4).

In analyses stratified by demographic characteristics (**Figure 4**), post-infection vaccine doses were protective in both female (aHR 0.81 [0.76, 0.86]) and male individuals (aHR 0.83 [0.79, 0.87]). Post-infection vaccination was more protective for participants aged 60 years or older (aHR 0.73 [0.69, 0.78]) compared to other age groups. The estimated aHR for individuals who were asymptomatic during their first infection was 0.80 (0.74, 0.87), and for those who were symptomatic during the first infection was 1.01 (0.78, 1.29).

181 As a secondary analysis, we estimated vaccine effects by calendar time of 182 vaccination. Post-infection vaccine doses given within 30 and 90 days of the second 183 Omicron variant wave were associated with lower hazard of reinfection (aHRs 0.51 184 [0.44, 0.58], 0.67 [0.61, 0.74], respectively). Note that in this secondary analysis, 185 exposed and unexposed individuals were matched using propensity scores. We also 186 performed a secondary analysis by vaccine type: for example, we compared patients 187 who completed full vaccination before first infection and received a post-infection 188 Ad5-nCOV vaccine dose, with those who completed full vaccination before first 189 infection and did not receive post-infection vaccination; this approach was repeated 190 for inactivated vaccines and recombinant protein vaccines (**Table S5**). In this analysis, 191 the types of vaccines administered before infection often aligned between the post-192 infection vaccination group and the post-infection non-vaccination group. Post-193 infection Ad5-nCoV vaccine dose given to those had received full vaccination before 194 the first infection was associated with lower hazard of reinfection (0.67, 95% CI: 0.56, 195 0.80); a protective effect was also observed for other vaccine types: inactivated 196 vaccines (0.92, 95% CI: 0.87, 0.98) or recombinant protein vaccines (0.77, 95% CI: 197 0.64, 0.92). We performed an additional ad-hoc sensitivity analysis using a Cox 198 model that was not adjusted for the severity of the first infection. As shown in Figure

199 S2, our findings were not affected by the non-inclusion of disease severity in the200 survival analysis model.

201 **3 Discussion**

202 We aimed to estimate the added value of a vaccine dose given after SARS-CoV-203 2 infection in individuals who had received COVID-19 vaccination before the 204 emergence of the Omicron variant. Although quantification of the protective effect of 205 post-infection vaccination in individuals who have been both exposed to infection and 206 previously vaccinated is a public health policy priority, as in many settings this group 207 represents a large fraction of the population, studies on this question are often 208 complicated by the variable timing of infection, vaccination and reinfection. Here, we 209 leveraged the epidemiological history of COVID-19 in Shanghai municipality, where 210 exposure to first and second SARS-CoV-2 infections occurred during well-defined 211 periods of time, and large electronic databases allowed analyses of vaccination and 212 infection history. Our study showed that post-infection vaccination reduced the risk of 213 reinfection with the Omicron variant during a second, large surge of infections in the 214 city. We also assessed the impact of the timing of vaccination relative to the second 215 Omicron variant wave, and presented secondary and sensitivity analyses. This study 216 will be used to guide COVID-19 vaccination policy in the municipality of Shanghai, 217 and have implications for the rest of the country.

218 In Shanghai, COVID-19 vaccination started in February 2021 for individuals 219 aged between 18 and 59 years, and over the following months, both older residents and children were included in the vaccination programme[9]. By the time of the first 220 221 surge of Omicron variant infections, less than 70% of Shanghai residents aged 60 to 222 79 years had completed a primary vaccination series, and 40% had received a booster 223 dose[8]. This was the context in which the population in this municipality was 224 exposed to a first large epidemic of SARS-CoV-2 infections. The change in policy in 225 December 2022 that was associated with a significant increase in the number of 226 infections was our primary motivation to study the additional protection afforded by 227 post-infection vaccination. Indeed, although epidemiological studies have been 228 reported on the effect of vaccination against reinfection, primarily in Europe[10], 229 North America[11] and Middle East[12], there is limited evidence from settings 230 similar to that in Shanghai, where both the infection and vaccination histories, in 231 terms of vaccine types, differ considerably from those in most Western countries. As

individuals increasingly question the benefit of getting vaccinated after COVID-19recovery, evidence generated locally is necessary.

234 Previous studies have shown that infection alone can result in immune responses 235 that protect against Omicron variant reinfection. For example, a study in Qatar, with a 236 test-negative design, found that an earlier Omicron variant infection provided 237 protection against symptomatic BA.4 or BA.5 reinfection[13]. There are also different 238 types of evidence that support post-infection vaccination. In Israel, post-infection 239 vaccination protected against reinfection in individuals with no history of pre-240 infection vaccination[14], and prior SARS-CoV-2 infection was associated with lower 241 risk for breakthrough infection among individuals receiving the BNT162b2 or 242 mRNA-1273 vaccines in Qatar[15]. Further, a recent cohort study, performed in the 243 US, of previously infected individuals who were unvaccinated at the time of first 244 infection suggest that vaccination after recovery from COVID-19 decreased risk of 245 reinfection by approximately half[16], which was consistent with a case-control study 246 also conducted in the US[17]. Although our research question was different from 247 those in these studies, data from Shanghai suggest that post-infection vaccination in 248 individuals who had received at least one dose of SARS-CoV-2 vaccine before 249 infection provides protection against reinfection. We note that whilst post-infection 250 vaccination was protective for individuals who had received one or two vaccine doses 251 before the first Omicron variant wave, for those individuals who had received three 252 pre-infection vaccine doses, the evidence for a protective effect was limited. A 253 possible explanation relates to the timing of post-infection vaccination: for all 254 individuals with three pre-infection vaccine doses, the post-infection dose was given 255 in December 2022 and, as a few weeks are required for immunologic boosting, the 256 relatively short follow-up might have been insufficient to detect an effect. Similarly, 257 evidence that post-infection vaccination was protective for individuals who had 258 received booster vaccination before the spread of the first Omicron variant wave in 259 Shanghai was limited; the majority (793/810) of these individuals had 3 doses before 260 first Omicron variant infection.

In a secondary analysis that assessed the impact of the timing of the postinfection vaccination on the estimated effect, we observe that vaccination within 30 and 90 days before the second surge of Omicron variant provided different degrees of protection, consistent with waning of immunity even in individuals with multiple

265 vaccine doses and history of infection[18]. As the duration of follow-up in our study 266 was relatively short, we were not able to analyze immunity duration over longer 267 periods of time after the start of the second Omicron variant wave. This observation 268 has implications for COVID-19 vaccination programmes: for example, under 269 perfectly functioning logistics, it is possible that timing of vaccination campaigns, 270 including for individuals who have been both previously infected and vaccinated, 271 might be optimal if launched immediately after increase in incidence (e.g. linked to a 272 new variant), rather than immediately after the end of a wave of infections.

273 In our analyses stratified by demographic characteristics, the protective effect of 274 post-infection vaccination was higher among patients who were 60 years of age or 275 older than among younger individuals. As older individuals are more likely to suffer 276 severe disease, including in settings similar to Shanghai [6], this finding suggests that 277 vaccination of individuals in this age group, even after previous infection and 278 vaccination, is beneficial. Similar to the findings of Ghorbani et al[19], we also found 279 that the rate of reinfection in females was lower than in males; however, the 280 protective effect of post-infection vaccination was similar in the two groups.

281 We also observed greater protection after an Ad5-nCoV post-infection 282 vaccination in individuals who were fully vaccinated before their first SARS-CoV-2 283 infection compared to post-infection vaccination with other vaccine types. Note 284 however that not all post-infection doses were of the same type of pre-infection 285 vaccine doses. Another stratified analysis revealed that the protective effect of 286 additional doses was different in individuals who had asymptomatic presentations of 287 the first infection versus those who had symptomatic disease (aHR 0.80 [0.74, 0.87] 288 and 1.01 [0.78, 1.29]). This could be related to different immune responses after 289 infections with different severities. Indeed, reduced antibody response after the initial 290 SARS-CoV-2 infection has been associated with incidence of reinfections. For 291 example, in the study by Islamoglu and colleagues [20], it was observed that antibody 292 responses against SARS-CoV-2 were protective against COVID-19 reinfection. 293 Consistently, in the Republic of Korea, CD4⁺ T-cell responses tended to be greater in 294 patients who had severe disease[21]. In agreement with these studies, that had 295 different designs, our analysis suggests that individuals who had severe or critical 296 COVID-19 had a lower risk of reinfection compared to those who were asymptomatic 297 (see Table 1). Note that individuals who were asymptomatic and those with mild

symptoms during the first infection had comparable rates of reinfection. However,
individuals with unknown disease severity during the first infection had a higher
reinfection rate compared to those with documented clinical severity.

301 Strengths of our study include: the well-defined timing of first infections and 302 reinfections in Shanghai, linked to the two Omicron variant waves; detailed 303 information on vaccination based on a citywide system; mass screening for SARS-304 CoV-2 infections during the first Omicron variant surge; free testing during the 305 second Omicron variant wave. Further, to prevent immortal time bias, a common 306 problem in epidemiological studies where treatment/exposure assignment is not 307 aligned with the start of follow-up, we performed survival analysis that used a time 308 varying exposure variable. The insights from our study are also likely generalizable to 309 similar urban settings facing distinct waves of SARS-CoV-2 infections and that 310 adopted the same vaccine types. However, our study also has limitations. Firstly, 311 information on key variables, such as occupation, household registration, clinical 312 severity during the first infection, was missing for a non-negligible fraction of the 313 study population. Although in the primary analysis we performed adjustment for 314 likely confounders, and in the secondary analysis we used propensity score matching, 315 as in other observational studies, we cannot rule out the possibility of residual 316 confounding, which in this context could be related to comorbidities that might affect 317 both the decision to vaccinate after infection and risk of reinfection. Differences in 318 healthcare-seeking behavior could also bias case ascertainment between post-infection 319 vaccinated and unvaccinated individuals[22]. Although we restricted the study 320 population to individuals who had received at least one pre-infection vaccination, 321 which might have led to a higher degree of homogeneity in healthcare-seeking 322 behaviour compared to that in the total population, it is possible that this bias might 323 have affected our estimates. For example: individuals who were more health 324 conscious might have been more likely to receive post-infection vaccination and also 325 more likely to seek medical care or testing when reinfected, and this would have 326 biased results toward the null; it is, however, also conceivable that these individuals 327 were more likely to avoid contact with potentially infectious persons, which could 328 have biased results in the opposite direction. Finally, data on the severity of infections 329 during the second wave were not available, which prevented analyses of clinical 330 outcomes other than infections (e.g. COVID-19-related hospitalization or death).

Although some previous studies [23-25] estimated similar or higher vaccine effectiveness against severe outcomes compared to outcomes that presumably include both milder and severe presentations, this pattern was not observed in all studies. Epidemiologists and public health officials who will use our results to define vaccination policy should thus take into account the fact that our analysis does not capture all benefits of post-infection vaccinations.

337 Conclusions

338 Although SARS-CoV-2 vaccination, including booster doses, is recommended 339 by the public health authorities in Shanghai to reduce the local disease burden caused 340 by COVID-19, there is increasing unwillingness in the population to receive 341 additional vaccine doses, and vaccine fatigue has been frequently reported. Our study 342 provides evidence that there is additional value for individuals who have been 343 vaccinated in receiving vaccine doses after infections. It also suggests that vaccination 344 programmes need to be linked to efficient surveillance for new infections so that 345 public health authorities can maximize impact of additional doses, including in this 346 group of patients.

347 4 Materials and methods

348 4.1 Study setting and participants

349 During the first Omicron variant wave, the entire city of Shanghai entered a 350 lockdown phase on April 1, 2022; and on June 1, 2022, the local government declared 351 the end of the city-wide lockdown[6]. Residents (citizens, including immigrants from 352 other provinces, and foreigners) in Shanghai, a provincial-level municipality in China 353 with a population of more than 25 million people, underwent several rounds of SARS-354 CoV-2 RT-PCR testing between April 1 and May 31, 2022. This study included 355 individuals diagnosed with their first SARS-CoV-2 infection between April 1 and 356 May 31, 2022 in the Pudong District, which is a large and densely populated district 357 of Shanghai spanning an area of 1,210 square kilometers with a permanent resident 358 population of 5.57 million, served by more than 30 hospitals and 60 community 359 health centers [26]; both individuals who were diagnosed by mass screening and those 360 with symptoms who were seen by healthcare professionals were included. 361 Information on infection history as well as data on demographic variables (sex at birth, 362 and age) were provided by the Center for Disease Control and Prevention in Shanghai, 363 China.

364 Additional information (e.g. on occupation, residence, clinical severity and 365 symptoms of first infection) was available for patients with hospital records and those 366 who were transferred to a hospital. The recorded clinical severity was categorized as 367 asymptomatic, mild, moderate, severe, or critically ill[27, 28]. During the first 368 Omicron variant wave in Shanghai, many Fangcang shelter hospitals were rapidly 369 converted into facilities to treat COVID-19 patients and made important contributions 370 in providing adequate healthcare to patients with mild to moderate symptoms, and 371 preventing further viral transmission in the community[29]. The efficient referral and 372 transfer mechanisms in the local communities meant that the majority of patients were 373 admitted to Fangcang shelter hospitals one or two days after testing positive for 374 SARS-CoV-2[30]. However, many patients were either admitted to hospital without 375 complete clinical information or not transferred to other hospitals; for these study 376 participants, information on clinical severity was often missing.

377 4.2 Study design and eligibility criteria

378 There was a second surge of Omicron variant cases from December 2022; and 379 from January 2023, free nucleic acid testing services were no longer offered in 380 Shanghai, and mandatory PCR testing on all personnel ceased. After this change, the 381 cost of an individual test was 16 yuan (US\$2.33)[31]. For this reason, the outcome 382 variable in our analysis was based on reinfection data collected prior to January 2023. 383 Reinfection-related death was defined as death within 30 days of a SARS-CoV-2 384 reinfection[10]; individuals who died from reasons unrelated to COVID-19 between 385 the two Omicron variant waves were excluded. Individuals were also excluded if the 386 date of first infection was missing. As the reasons why some individuals refused to 387 receive vaccination varied and were often unknown[32], our analysis focused on 388 individuals who had received at least one vaccine dose before the first SARS-CoV-2 389 infection.

390 *4.3 Vaccination and reinfection data*

The Shanghai Group Immunization System captures all vaccine administrations in the municipality and is updated daily. This system is linked to the National Immunization Program Information System, which also includes national identification-matched COVID-19 vaccinations received outside of Shanghai[8]. Vaccination status was categorized in accordance with national technical recommendations for COVID-19 vaccination[8]: unvaccinated, partially vaccinated,

fully vaccinated and fully vaccinated with booster dose (here, also referred to as
booster vaccination). Here, inactivated vaccines refer to Sinovac-CoronaVac,
Sinopharm/BIBP COVID-19 vaccine, and Sinopharm/WIBP COVID-19 vaccine;
Ad5-vectored vaccine refers to Cansino Ad5-nCoV-S COVID-19 vaccine; and
recombinant protein vaccine refers to recombinant COVID-19 vaccine (CHO cell),
Anhui Zhifei Longcom Biopharmaceutical Institute of Microbiology.

As in other epidemiological studies[19, 33], we defined reinfection as a positive SARS-CoV-2 RT-PCR or rapid antigen test at least 90 days after the first positive test. Phylogenetic analysis coupled with contact tracing data revealed community transmission of Omicron BA.5.2 sublineage in Shanghai[9]; the subvariant was estimated to have caused ~90% of infections during the second Omicron variant wave. **4.4 Statistical analysis**

409 Continuous variables are summarized as medians and interquartile ranges (IQR), 410 and categorical variables, as counts, proportions or percentages. Cumulative incidence 411 of reinfections was calculated and expressed as the number of reinfected individuals 412 per 100 participants. Cox proportional hazards models with a time varying exposure 413 variable corresponding to post-infection vaccination were used to estimate adjusted 414 hazard ratios (aHR). In this analysis, time to reinfection was the outcome, and post-415 infection vaccination, the exposure of interest; models were adjusted for sex, age, 416 residence, occupation and clinical severity of the first SARS-CoV-2 infection. As, due 417 to social distancing measures, the number of SARS-CoV-2 infections diagnosed 418 between May and November 2022 in Shanghai was low (N = 89 individuals), the start 419 of the follow-up in the survival analysis was on December 1, and for each participant, 420 the follow-up continued until January 3, 2023 or confirmed SARS-CoV-2 reinfection, 421 whichever occurred earlier. We note that by using this approach, both the start of the 422 follow-up and the eligibility (which required confirmed SARS-CoV-2 infection 423 during the initial Omicron variant wave, and being at risk of infection when the 424 second Omicron variant wave occurred in December) are temporally aligned. On the 425 other hand, for some participants, the time of exposure (post-infection vaccination) 426 occurred after time zero, which could potentially lead to immortal time bias[34]; for 427 this reason, the exposure variable was as time-varying. We also assessed whether this 428 effect was modified by demographic characteristics.

429 We conducted a secondary analysis to estimate the protection afforded by post-

430 infection vaccination before the second Omicron variant wave (that is, only vaccine 431 doses received before December 2022 were used in defining the exposure variable); 432 this analysis was stratified by time intervals between post-infection vaccination and 433 the second Omicron variant wave, and by post-infection vaccine type (for individuals 434 who had the same vaccination status or the same number of doses before first 435 infection). For this secondary analysis, propensity score matching was used to 436 improve comparability between the exposed and unexposed groups; the propensity 437 score was calculated using a logistic regression model with all available baseline 438 characteristics, and a one-to-one matching was performed using the nearest neighbor 439 matching method with a caliper width of 0.20[35]. We assessed the balance of 440 covariates after matching using standardized mean differences (SMD), and considered 441 a value of less than 0.1 to be indicative of adequate matching (Table S6-8). All 442 statistical analyses were performed using R.4.1.1 software (Foundation for Statistical 443 Computing, Vienna, Austria; <u>https://www.r-project.org</u>). We followed the 444 Strengthening the reporting of observational studies in epidemiology (STROBE) 445 recommendations, and the STROBE checklist is provided in the Supplementary 446 Appendix (**Table S9**)

447 Acknowledgments

- 448 We gratefully acknowledge all participants in this study.
- 449

450 Additional information

451 Funding

Funder	Grant reference number	Author	
Key Discipline Program of Pudong New Area Health System	PWZxk2022-25	Pengfei Deng	
Development and Application of Intelligent Epidemic Surveillance and Artificial Intelligence Analysis System	21002411400	Weibing Wang	
Shanghai Three-year Action Plan to Strengthen the Construction of Public Health System	GWVI-11.2-XD08	Caoyi Xue	
Key Disciplines supported by Shanghai Municipal Health Commission	GWVI-11.1-02	Caoyi Xue	

	Shanghai Municipal Health Commission Clinical Research Program	20214Y0020	Ye Yao				
	General Program of Natural Science Foundation of Shanghai Municipality	22ZR1414600	Ye Yao				
	Young Health Talents Program of Shanghai Municipality	2022YQ076	Ye Yao				
	The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.						
452	Author contributions						
453	BZ, BG, WW and YY designed the st	tudy. CX, PD and BZ extra	cted the data and				
454	constructed the database. BZ, JT and XL analyzed the data. BZ and WW drafted the						
455	manuscript-original draft. BG, XC, Y	Y and WW conducted critic	al revisions of the				
456	manuscript—review and editing. All authors read and approved the final manuscript.						
457	Ethics						
458	The study was approved by the Ethical Review Committee in the Shanghai Pudong						
459	New Area Center for Disease Control and Prevention (approval number: PDCDCLL-						
460	20220801-001).						
461	Consent for publication						
462	Not applicable.						
463	Competing interests						
464	The authors declare that they have no known competing financial interest or personal						
465	relationship that could influence the work reported in this paper.						
466							
467							
468	Additional files						
469	Supplementary files						
470	Table S1. Descriptive overview of the st	tudy population.					
471	Table S2. Characteristics of vaccination distribution among study population.						
472	Table S3. Cross-classification based on	the number of vaccine dose	es received before				
473	the first infection and vaccination status						
474	Table S4. Effect of post-infection va	accination in individuals w	ith no history of				
475	vaccination before infection.						

- 476 Table S5. Effect of vaccination after first infection against SARS-CoV-2 reinfection
- 477 stratified by sequence of vaccination dose and vaccination status before first infection.
- 478 Table S6. Baseline demographic characteristics of unvaccinated and vaccinated
- 479 groups after first infection stratified by dose received before first infection.
- 480 Table S7. Baseline demographic characteristics of unvaccinated and vaccinated
- 481 groups after first infection stratified by intervals before the policy change.
- 482 Table S8. Baseline demographic characteristics of unvaccinated and vaccinated
- 483 groups after first infection stratified by vaccination status prior infection.
- 484 Table S9. STROBE Statement.
- Figure S1. Vaccination status coverage in the study population.
- 486 Figure S2. Effect of post-infection vaccination on SARS-CoV-2 reinfection stratified
- 487 by pre-infection vaccination and not adjusted for the severity of the first infection.
- 488 Data availability
- 489 The individual-level data used in this study are sensitive and cannot be publicly
- 490 shared. Requests for data should be made to the Shanghai Pudong New Area Center
- 491 for Disease Control and Prevention.

492 **References**

493	1.	Pan Y, Wang L, Feng Z, Xu H, Li F, Shen Y, Zhang D, Liu WJ, Gao GF, Wang Q:
494		Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological
495		and phylogenetic analysis. Lancet 2023, 401(10377):664-672.
496	2.	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R <i>et al</i> .
497		A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med
498		2020, 382 (8):727-733.
499	3.	Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji UJ,
500		Bester PA, Boni MF, Chand M et al. Rapid epidemic expansion of the SARS-CoV-2
501		Omicron variant in southern Africa. Nature 2022, 603(7902):679-686.
502	4.	Zhou Y, Zhi H, Teng Y: The outbreak of SARS-CoV-2 Omicron lineages, immune
503		escape, and vaccine effectivity. <i>J Med Virol</i> 2023, 95 (1):e28138.
504	5.	Li J, Lai S, Gao GF, Shi W: The emergence, genomic diversity and global spread of
505		SARS-CoV-2. Nature 2021, 600(7889):408-418.
506	6.	Chen X, Yan X, Sun K, Zheng N, Sun R, Zhou J, Deng X, Zhuang T, Cai J, Zhang J
507		et al. Estimation of disease burden and clinical severity of COVID-19 caused by
508		Omicron BA.2 in Shanghai, February-June 2022. Emerg Microbes Infect 2022,
509		11 (1):2800-2807.
510	7.	Zheng L, Liu S, Lu F: Impact of National Omicron Outbreak at the end of 2022 on the
511		future outlook of COVID-19 in China. Emerg Microbes Infect 2023, 12(1):2191738.
512	8.	Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, Ren J, Li Z, Guo X, Tao F <i>et al</i> .
513		Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai:
514		retrospective cohort study. Nat Commun 2023, 14(1):2009.
515	9.	Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, Ren J, Li Z, Guo X, Tao F <i>et al</i> .
516		Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2
517		Omicron BA. 2 variant infection, severe illness, and death. BMC Med 2022, 20(1):400.
518	10.	Nielsen KF, Moustsen-Helms IR, Schelde AB, Gram MA, Emborg HD, Nielsen J,
519		Hansen CH, Andersen MA, Meaidi M, Wohlfahrt J et al. Vaccine effectiveness against
520		SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A
521		Danish nationwide study. PLoS Med 2022, 19(11):e1004037.
522	11.	Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, Selemon A, Whelan M, Premji Z,
523		Issa H et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid
524		immunity against the omicron variant and severe disease: a systematic review and
525		meta-regression. Lancet Infect Dis 2023, 23(5):556-567.
526	12.	Gazit S, Saciuk Y, Perez G, Peretz A, Ben-Tov A, Stuart EA, Patalon T: Hybrid
527		immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2
528		infection and single dose of the BNT162b2 vaccine in children and adolescents: a
529		target trial emulation. Lancet Microbe 2023, 4(7):e495-e505.
530	13.	Altarawneh HN, Chemaitelly H, Ayoub HH, Hasan MR, Coyle P, Yassine HM, Al-


531		Khatib HA, Smatti MK, Al-Kanaani Z, Al-Kuwari E <i>et al.</i> Protective Effect of Previous
532		SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. N Engl J Med
533		2022, 387 (17):1620-1622.
533 534	14.	Hammerman A, Sergienko R, Friger M, Beckenstein T, Peretz A, Netzer D, Yaron S,
	14.	
535 536		Arbel R: Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. N
536 537	4 5	Engl J Med 2022, 386 (13):1221-1229.
537	15.	Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib
538		HA, Tang P, Hasan MR, Coyle P, Al Kanaani Z <i>et al</i> . Association of Prior SARS-CoV -
539		2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
540		<i>Jama</i> 2021, 326 (19):1930-1939.
541	16.	Lewis N, Chambers LC, Chu HT, Fortnam T, De Vito R, Gargano LM, Chan PA,
542		McDonald J, Hogan JW: Effectiveness Associated With Vaccination After COVID-19
543		Recovery in Preventing Reinfection. JAMA Netw Open 2022, 5(7):e2223917.
544	17.	Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K: Reduced Risk of
545		Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June
546		2021 . MMWR Morb Mortal Wkly Rep 2021, 70 (32):1081-1083.
547	18.	Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N,
548		Natarajan K, Stenehjem E, Grannis SJ <i>et al</i> . Waning of vaccine effectiveness against
549		moderate and severe covid-19 among adults in the US from the VISION network: test
550		negative, case-control study. Bmj2022, 379:e072141.
551	19.	Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari
552		SS: Epidemiologic characteristics of cases with reinfection, recurrence, and hospital
553		readmission due to COVID-19: A systematic review and meta-analysis. J Med Virol
554		2022, 94 (1):44-53.
555	20.	IslamogIu MS, Cengiz M, Uysal BB, Ikitimur H, Ozdemir Z, KaramehmetogIu A,
556		Akbulut AE, Bakdur AN, Ozdemir A, Kayıkcıoglu H <i>et al</i> . Relationship between
557		Antibody Levels and SARS-Cov-2 Reinfection. Ann Clin Lab Sci 2021, 51(6):750-755.
558	21.	Kang CK, Kim M, Lee S, Kim G, Choe PG, Park WB, Kim NJ, Lee CH, Kim IS, Jung
559		K et al. Longitudinal Analysis of Human Memory T-Cell Response According to the
560		Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome
561		Coronavirus 2 Infection. J Infect Dis 2021, 224(1):39-48.
562	22.	Yung CF, Pang D, Kam KQ, Lye DC, Ong B, Chong CY, Tan KB: BNT162b2 vaccine
563		protection against omicron and effect of previous infection variant and vaccination
564		sequence among children and adolescents in Singapore: a population-based cohort
565		study. Lancet Child Adolesc Health 2023
566	23.	م Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, Lipsitch M,
567		Reis BY, Balicer RD, Dagan N: Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine
568		in a Nationwide Setting. <i>N Engl J Med</i> 2022, 386 (17):1603-1614.
569	24.	Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, Fell DB, Austin PC,
000	£ 1.	

570		Schwartz KL, Sundaram ME <i>et al</i> . Effectiveness of COVID-19 vaccines against
571		symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in
572		Ontario. Nat Microbiol 2022, 7(3):379-385.
573	25.	Sacco C, Del Manso M, Mateo-Urdiales A, Rota MC, Petrone D, Riccardo F, Bella A,
574		Siddu A, Battilomo S, Proietti V et al. Effectiveness of BNT162b2 vaccine against
575		SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a
576		retrospective analysis of January-April, 2022. Lancet 2022, 400(10346):97-103.
577	26.	Pudong New Area Builds Full-Coverage Medical Service Chain
578		[https://enshanghaiacademy.shu.edu.cn/info/1013/2339.htm]
579	27.	Chen Z, Deng X, Fang L, Sun K, Wu Y, Che T, Zou J, Cai J, Liu H, Wang Y <i>et al</i> .
580		Epidemiological characteristics and transmission dynamics of the outbreak caused by
581		the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study. Lancet
582		<i>Reg Health West Pac</i> 2022, 29 :100592.
583	28.	Ge Y, Martinez L, Sun S, Chen Z, Zhang F, Li F, Sun W, Chen E, Pan J, Li C <i>et al</i> .
584		COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With
585		COVID-19: A Population-Based Cohort Study in Zhejiang Province, China. JAMA
586		Intern Med 2021, 181(10):1343-1350.
587	29.	Zhang X, Zhang W, Chen S: Shanghai's life-saving efforts against the current
588		omicron wave of the COVID-19 pandemic. Lancet 2022, 399(10340):2011-2012.
589	30.	Ye L, Li WF, Shao J, Xu Z, Ju J, Xu H: Fighting Omicron epidemic in China: Real-
590		world big data from Fangcang shelter hospital during the outbreak in Shanghai 2022.
591		<i>J Infect</i> 2022, 85 (4):436-480.
592	31.	No more free PCR tests in Shanghai from Sunday
593		[https://www.shine.cn/covid19/2301064857/]
594	32.	Wu J, Li Q, Silver Tarimo C, Wang M, Gu J, Wei W, Ma M, Zhao L, Mu Z, Miao Y:
595		COVID-19 Vaccine Hesitancy Among Chinese Population: A Large-Scale National
596		Study. Front Immunol 2021, 12:781161.
597	33.	Investigative criteria for suspected cases of SARS-CoV-2 reinfection (ICR)
598		[https://stacks.cdc.gov/view/cdc/96072]
599	34.	Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I: Specifying a target trial
600		prevents immortal time bias and other self-inflicted injuries in observational analyses.
601		<i>J Clin Epidemiol</i> 2016, 79 :70-75.
602	35.	Ueno M, Komeda K, Kosaka H, Nakai T, Nomi T, Iida H, Tanaka S, Ikoma H,
603		Matsuda K, Hirokawa F <i>et al</i> . Prognostic impact of neoadjuvant chemotherapy in
604		patients with synchronous colorectal liver metastasis: A propensity score matching
605		comparative study. Int J Surg 2021, 94:106106.
606		

607 Table 1. Characteristics of the study population and reinfection rate by post-infection vaccination status. Here, reinfection rate refers to 608 the percentage of the relevant study subpopulation with evidence of reinfection between December 1, 2022 and January 3, 2023. Note that for 609 the variables on region, occupation, and clinical severity, data are missing for large fractions of the study population. Note also that information 610 was only available on sex at birth, but not on gender.


		All		No post-infection vaccination		Post-infection vaccination	
	Characteristics	N (%)	Reinfection rate, % (95% CI).	N (%)	Reinfection rate, % (95% CI).	N (%)	Reinfection rate, % (95% CI).
Overall		199,312	24.4 (24.2, 24.6)	183,165	24.7 (24.5, 24.9)	16,147	21.5 (20.8, 22.2)
Sex	Male	112,672 (56.5)	26.1 (25.8, 26.4)	104,002 (56.8)	26.4 (26.1, 26.7)	8,670 (53.7)	22.3 (21.3, 23.3)
	Female	85,804 (43.1)	22.4 (22.1, 22.7)	78,403 (42.8)	22.9 (22.6, 23.2)	7,401 (45.8)	17.4 (16.4, 18.3)
Age, years	0-6	1,736 (0.9)	7.0 (5.8, 8.3)	1,569 (0.9)	6.6 (5.4, 8.0)	167 (1.0)	10.2 (6.2, 15.9)
	7-19	10,762 (5.4)	13.0 (12.3, 13.7)	10,347 (5.6)	12.9 (12.3, 13.6)	415 (2.6)	14.7 (11.4, 18.8)
	20-39	75,955 (38.1)	22.4 (22.1, 22.8)	71,005 (38.8)	22.7 (22.3, 23.0)	4,950 (30.7)	19.1 (17.9, 20.3)
	40-59	74,680 (37.5)	29.4 (29.0, 29.8)	70,569 (38.5)	29.6 (29.2, 30.0)	4,111 (25.5)	25.8 (24.2, 27.4)
	60+	35,903 (18.0)	22.6 (22.1, 23.1)	29,446 (16.1)	23.7 (23.1, 24.2)	6,457 (40.0)	17.6 (16.6, 18.6)
Regions	Shanghai	44,259 (22.2)	18.9 (18.5, 19.3)	41,250 (22.5)	19.4 (19.0, 19.9)	3,009 (18.6)	11.9 (10.7, 13.1)
	Other provinces	44,959 (22.6)	20.9 (20.5, 21.3)	43,045 (23.5)	21.0 (20.6, 21.5)	1,914 (11.9)	18.2 (16.4, 20.2)
Occupations	Preschoolers and students	12,232 (6.1)	12.1 (11.5, 12.7)	11,677 (6.4)	12.0 (11.4, 12.6)	555 (3.4)	13.2 (10.4, 16.4)
	Employed	29,537 (14.8)	20.8 (20.2, 21.3)	28,343 (15.5)	20.8 (20.3, 21.4)	1,194 (7.4)	18.8 (16.4, 21.3)
	Retired	37,482 (18.8)	22.5 (22.0, 23.0)	30,955 (16.9)	23.5 (23.0, 24.1)	6,527 (40.4)	17.5 (16.5, 18.5)
	Working age not in labor ^{\dagger}	5,606 (2.8)	21.0 (19.8, 22.2)	5,311 (2.9)	21.5 (20.3, 22.8)	295 (1.8)	11.5 (8.1, 15.9)
Clinical	Asymptomatic	81,584 (40.9)	19.9 (19.6, 20.2)	77,057 (42.1)	20.3 (19.9, 20.6)	4,527 (28.0)	14.1 (13.1, 15.3)
severity*	Mild/moderate	7,602 (3.8)	19.9 (18.9, 21.0)	7,216 (3.9)	20.1 (19.1, 21.2)	386 (2.4)	16.6 (12.9, 21.0)
	Severe or critical	32 (0.0)	15.6 (5.9, 34.3)	22 (0.0)	13.6 (3.8, 36.4)	10 (0.1)	20.0 (4.0, 64.1)

611 CI: confidence interval; ^{\dagger} people of working age (≥ 18 years) unemployed or not in the labor force (disabled); *Clinical severity of first infection.




612

Figure 1. Flow chart describing the selection of participants for the analysis. The number of individuals in this figure is not the same as some of the numbers in **Table 1** because of missing data in key variables. Note that in the bottom part of the chart, related to secondary analyses, the boxes represent overlapping sets of study participants; in other words, some individuals included in the secondary analyses that correspond to the left box were also included in analyses corresponding to the box on the right.



622 Figure 2. Vaccination coverage and cumulative incidence of SARS-CoV-2 623 reinfection in the study population. Panel A presents the percentages of the study 624 population vaccinated over time. The cumulative incidence of SARS-CoV-2 625 reinfections is presented by the number of vaccination doses before (panels) and after 626 (lines) first infection (panels B-C). Shaded regions: 95% CIs. 1V-I, 2V-I represented 627 1, and 2 vaccine doses before infection, respectively; 1V-I-V, 2V-I-V corresponds to 628 1 and 2 doses before infection, then post-infection vaccination, respectively. As 629 mentioned in the *Results* section, 142 and 144 study participants who received one 630 and two pre-infection vaccine doses received two post-infection vaccine doses. We do 631 not show the corresponding plot for those individuals who received 3 pre-infection 632 doses as their post-infection dose was after the start of the follow-up, in December. 633

634



637 Figure 3. Effect of post-infection vaccination on SARS-CoV-2 reinfection 638 stratified by pre-infection vaccination. Error bars (95% CIs) and circles represent 639 aHR for SARS-CoV-2 reinfection estimated using Cox proportional hazards models. 640 V-I-V, 1V-I-V, 2V-I-V, 3V-I-V corresponds to any pre-infection vaccination, 1, 2 and 641 3 vaccine doses before infection, then vaccination, respectively; they were compared 642 to V-I, 1V-I, 2V-I, 3V-I, respectively. Partial V-I-V, Full V-I-V and Booster V-I-V 643 represent partial vaccination, full vaccination and booster vaccination before infection, 644 followed by post-infection vaccination, respectively. The number of doses received by 645 individuals with partial versus full (and full with booster) vaccination depends on the 646 type of SARS-CoV-2 vaccine received; in Table S3 we present a cross-classification 647 of participants in the analytic population by these vaccination-related categorical 648 variables.

- 649
- 650
- 651
- 652
- 653
- 654

Subgroup	Reinfection rate (Unvaccinated Group)	Reinfection rate (Vaccinated Grou	. (qt	aHR (95% CI)
Sex			1	
Female	22.74 (22.41, 23.07)	17.53 (16.68, 18.41)	H H H	0.81 (0.76 to 0.86)
Male	26.30 (25.99, 26.61)	22.36 (21.46, 23.28)	H H 1	0.83 (0.79 to 0.87)
Age, years				
0-6	6.57 (5.39, 7.93)	10.56 (6.57, 16.15)	+ + •	+ 1.45 (0.84 to 2.50)
7-19	12.90 (12.22, 13.60)	14.88 (11.65, 18.74)	· · · · · · · · · · · · · · · · · · ·	1.09 (0.84 to 1.41)
20-39	22.59 (22.24, 22.94)	19.05 (17.98, 20.17)	H +	0.83 (0.78 to 0.89)
40-59	29.52 (29.12, 29.92)	25.62 (24.25, 27.05)	H e -1	0.89 (0.83 to 0.94)
60+	23.33 (22.78, 23.88)	17.77 (16.84, 18.73)	H H H	0.73 (0.69 to 0.78)
Region				
Shanghai	19.24 (18.82, 19.66)	13.04 (11.96, 14.19)	H e -1	0.70 (0.63 to 0.78)
Other provinces	20.89 (20.46, 21.32)	19.75 (18.05, 21.58)	⊢⊣	0.98 (0.88 to 1.10)
Occupation			1	
Preschoolers and students	11.97 (11.35, 12.61)	13.32 (10.65, 16.47)	·	1.12 (0.88 to 1.42)
Employed	20.73 (20.20, 21.26)	19.68 (17.59, 21.96)		1.08 (0.94 to 1.23)
Working age not in labor	21.42 (20.20, 22.70)	12.67 (9.39, 16.75)		0.60 (0.43 to 0.85)
Retired	23.20 (22.67, 23.75)	17.64 (16.73, 18.60)	H H	0.73 (0.69 to 0.78)
Symptom (first infection)			1	
Asymptomatic	20.09 (19.78, 20.41)	15.46 (14.48, 16.48)	H :	0.80 (0.74 to 0.87)
Symptomatic	19.96 (18.95, 21.01)	16.73 (13.53, 20.46)	·•'	1.01 (0.78 to 1.29)
			04 05 06 07 08 09 10 11 12 13 14 15	16
			Lower hazard ratio Higher hazard r	-He

655

656 Figure 4. Vaccine-related protection against SARS-CoV-2 reinfection stratified

657 by demographic characteristic. The vertical dotted line at 1.0 indicates no effect on

- 658 protection.
- 659
- 660
- 661
- 662
- 663